A groundbreaking FDA approval has introduced a new treatment option specifically designed for colorectal cancer patients with ...

Colon cancer rates are surging worldwide, especially among younger and relatively healthy people, making it more important ...

Pfizer’s BRAFTOVI combination regimen receives US FDA approval for treatment of metastatic colorectal cancer: New York Monday, December 23, 2024, 10:00 Hrs [IST] Pfizer Inc anno ...

Cases of colorectal cancer have been rapidly increasing among young adults, so we spoke to a doctor to get some helpful tips.

Mainz Biomed has announced a partnership with Quest Diagnostics to support the commercialisation of its NextGen colorectal ...

Colon cancer screening is only effective if you complete the test. With 53,000 Americans expected to die from colon cancer in ...

Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed” or the "Company”), a molecular genetics diagnostic company specializing in ...

One’s biological age, which measures the body’s physiological state, may help predict who is at risk for developing colon ...

From detecting early disease to guiding treatment plans, clinicians are finding ctDNA testing increasingly important.

Special Report: Predictive cancer diagnostics company Rhythm Biosciences (ASX:RHY) is ending 2024 on a high reporting it had ...

The firm will test IMC-R117C alone and with other drugs in patients who are HLA-A*02:01 positive and have PIWIL1-expressing colorectal and other cancers.

Improvements in cancer prevention and screening have averted more deaths than treatment advances over the past 45 years.